ZYME Stock Analysis: Zymeworks Common Stock | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.936m USD | 12M Return: 104.3% | Charts, Fundamentals & Technical Analysis

Bispecific Antibodies, Antibody-Drug Conjugates, Cancer Therapeutics, T Cell Engagers
Total Rating 27
Safety 38
Buy Signal 0.49
Biotechnology
Industry Rotation: +30.9
Market Cap: 1.94B
Avg Turnover: 15.6M
Risk 3d forecast
Volatility49.8%
VaR 5th Pctl8.41%
VaR vs Median2.50%
Reward TTM
Sharpe Ratio1.51
Rel. Str. IBD83.6
Rel. Str. Peer Group44.8
Character TTM
Beta0.990
Beta Downside0.360
Hurst Exponent0.513
Drawdowns 3y
Max DD45.75%
CAGR/Max DD1.09
CAGR/Mean DD3.21
EPS (Earnings per Share) EPS (Earnings per Share) of ZYME over the last years for every Quarter: "2021-06": -1.31, "2021-09": -1.17, "2021-12": -0.76, "2022-03": -1.19, "2022-06": -0.97, "2022-09": -0.72, "2022-12": 4.65, "2023-03": -0.36, "2023-06": -0.76, "2023-09": -0.41, "2023-12": -0.2, "2024-03": -0.42, "2024-06": -0.49, "2024-09": -0.39, "2024-12": -0.31, "2025-03": -0.3, "2025-06": 0.03, "2025-09": -0.26, "2025-12": -0.55, "2026-03": -0.59,
Last SUE: -1.67
Qual. Beats: -1
Revenue Revenue of ZYME over the last years for every Quarter: 2021-06: 1.771, 2021-09: 4.395, 2021-12: 19.87, 2022-03: 1.916, 2022-06: 5.442, 2022-09: 2.631, 2022-12: 402.493, 2023-03: 35.578, 2023-06: 7.002, 2023-09: 16.506, 2023-12: 16.926, 2024-03: 10.03, 2024-06: 19.243, 2024-09: 16, 2024-12: 31.031, 2025-03: 27.11, 2025-06: 48.726, 2025-09: 27.614, 2025-12: 2.515, 2026-03: 2.408,
Rev. CAGR: -26.66%
Rev. Trend: -38.8%
Last SUE: -2.27
Qual. Beats: -2

Warnings

Altman Z'' In Financial Distress Zone

Tailwinds

Tailwind
Pullback 52w

Seasonality 9.2 years of data

Jan -6.4% 27
Feb -9.2% 36
Mar -6.5% 30
Apr +3.2% 22
May -2.7% 13
Jun +0.5% 8
Jul -5.3% 27
Aug +7.5% 50
Sep +0.6% 0
Oct +4.5% 17
Nov +11.6% 17
Dec -1.7% 15

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ZYME Zymeworks Common Stock

Zymeworks Inc. (NASDAQ: ZYME) is a clinical-stage biotechnology company based in Middletown, Delaware, that develops protein-based therapeutics for cancer, inflammation, and autoimmune diseases. Its pipeline is built on proprietary platforms, including the Azymetric multispecific antibody platform, a Drug Conjugate platform, the EFECT Fc-modification platform, and the ProTECT tumor-specific immune co-stimulation platform. Lead candidates include Ziihera (zanidatamab-hrii) for HER2-expressing tumors, Pasritamig for prostate cancer, and several antibody-drug conjugates (ZW191, ZW251, ZW220) and a TriTCE (ZW209) targeting solid tumors, alongside an early-stage bispecific (ZW1528) for chronic obstructive pulmonary disease.

The company operates in the small-cap segment of the biotechnology sector and was incorporated in 2003. Its business model relies heavily on strategic collaborations with major pharmaceutical partners, including Jazz Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Merck, and Janssen, which provide development funding and milestone payments typical of pre-commercial biotech firms.

Headlines to Watch Out For
  • Ziihera commercial uptake drives HER2 bispecific revenue growth
  • Strategic partnerships with Jazz and Daiichi generate milestone revenue
  • Clinical pipeline readouts for ADC candidates advance development
Piotroski VR-10 (Strict) 0.5
Net Income: -102.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.16 > 0.02 and ΔFCF/TA 3.32 > 1.0
NWC/Revenue: 430.7% < 20% (prev 258.5%; Δ 172.3% < -1%)
CFO/TA -0.16 > 3% & CFO -75.0m > Net Income -102.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.82 > 1.5 & < 3
Outstanding Shares: last quarter (74.7m) vs 12m ago -0.71% < -2%
Gross Margin: 86.72% > 18% (prev 88.01%; Δ -1.30% > 0.5%)
Asset Turnover: 17.98% > 50% (prev 21.95%; Δ -3.96% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' -3.53
A: 0.73 (Total Current Assets 385.7m - Total Current Liabilities 35.6m) / Total Assets 478.2m
B: -2.25 (Retained Earnings -1.07b / Total Assets 478.2m)
C: -0.23 (EBIT TTM -104.7m / Avg Total Assets 451.9m)
D: 0.52 (Book Value of Equity 163.6m / Total Liabilities 314.6m)
Altman-Z'' = -3.53 = D
Beneish M -3.96
DSRI: 0.22 (Receivables 4.67m/24.6m, Revenue 81.3m/93.4m)
GMI: 1.01 (GM 88.01% / 86.72%)
AQI: 0.66 (AQ_t 0.13 / AQ_t-1 0.20)
SGI: 0.87 (Revenue 81.3m / 93.4m)
TATA: -0.06 (NI -102.7m - CFO -75.0m) / TA 478.2m)
Beneish M = -3.96 (Cap -4..+1) = AAA
What is the price of ZYME shares?

As of July 08, 2026, the stock is trading at USD 26.72 with a total of 765,804 shares traded. Over the past week, the price has changed by +10.87%, over one month by +11.66%, over three months by +2.77% and over the past year by +104.28%.

Current recommended Stop Loss: 24.10 (which is 9.8% or 2.2 ATR below the current price).

Is ZYME a buy, sell or hold?

Zymeworks Common Stock has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ZYME.

  • StrongBuy: 7
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ZYME price?
Analysts Target Price 39.1 46.3%
Zymeworks Common Stock (ZYME) - Fundamental Data Overview as of 04 July 2026
Market Cap USD = 1.94b (1.94b USD * 1.0 USD.USD)
P/E Forward = 25.7069
P/S = 23.8206
P/B = 11.5473
Revenue TTM = 81.3m USD
EBIT TTM = -104.7m USD
EBITDA TTM = -94.3m USD
Long Term Debt = 13.8m USD (estimated: total debt 17.0m - short term 3.28m)
Short Term Debt = 3.28m USD (from shortTermDebt, last quarter)
Debt = 17.0m USD (from shortLongTermDebtTotal, last quarter) (leases 17.0m already included)
Net Debt = -163.6m USD (calculated: Debt 17.0m - CCE 180.6m)
Enterprise Value = 1.77b USD (1.94b + Debt 17.0m - CCE 180.6m)
 Interest Coverage Ratio = unknown (Ebit TTM -104.7m / Interest Expense TTM 0.0)
 EV/FCF = -22.69x (Enterprise Value 1.77b / FCF TTM -78.1m)
FCF Yield = -4.41% (FCF TTM -78.1m / Enterprise Value 1.77b)
FCF Margin = -96.10% (FCF TTM -78.1m / Revenue TTM 81.3m)
Net Margin = -126.3% (Net Income TTM -102.7m / Revenue TTM 81.3m)
Gross Margin = 86.72% ((Revenue TTM 81.3m - Cost of Revenue TTM 10.8m) / Revenue TTM)
Gross Margin QoQ = -18.23% (prev 32.76%)
Tobins Q-Ratio = 3.71 (Enterprise Value 1.77b / Total Assets 478.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 17.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -82.7m (EBIT -104.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.85 (Total Current Assets 385.7m / Total Current Liabilities 65.9m)
Debt / Equity = 0.10 (Debt 17.0m / totalStockholderEquity, last quarter 163.6m)
 Debt / EBITDA = 1.73 (negative EBITDA) (Net Debt -163.6m / EBITDA -94.3m)
 Debt / FCF = 2.09 (negative FCF - burning cash) (Net Debt -163.6m / FCF TTM -78.1m)
 Total Stockholder Equity = 271.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.72% (Net Income -102.7m / Total Assets 478.2m)
RoE = -37.79% (Net Income TTM -102.7m / Total Stockholder Equity 271.7m)
RoCE = -36.67% (EBIT -104.7m / Capital Employed (Equity 271.7m + L.T.Debt 13.8m))
 RoIC = -18.71% (negative operating profit) (NOPAT -82.7m / Invested Capital 441.8m)
 WACC = 9.37% (E(1.94b)/V(1.95b) * Re(9.45%) + D(17.0m)/V(1.95b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.44 | Cagr: 2.39%
 [DCF] Fair Price = unknown (Cash Flow -78.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.67 | # QB: -1
Revenue Correlation: -38.77 | Revenue CAGR: -26.66% | SUE: -2.27 | # QB: -2
EPS current Quarter (2026-06-30): EPS=-0.41 | Chg30d=-3.90% | Revisions=-57% | Analysts=9
EPS next Quarter (2026-09-30): EPS=1.66 | Chg30d=-14.26% | Revisions=+29% | Analysts=6
EPS current Year (2026-12-31): EPS=1.40 | Chg30d=+1.69% | Revisions=+12% | GrowthEPS=+229.5% | GrowthRev=+198.5%
EPS next Year (2027-12-31): EPS=0.32 | Chg30d=-37.62% | Revisions=+29% | GrowthEPS=-77.0% | GrowthRev=-38.5%
[Analyst] Revisions Ratio: +5% (up=9, down=8)